Compare Biocon with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs GLENMARK PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON GLENMARK PHARMA BIOCON /
GLENMARK PHARMA
 
P/E (TTM) x 31.6 15.1 209.9% View Chart
P/BV x 3.8 2.5 152.3% View Chart
Dividend Yield % 0.3 0.4 64.2%  

Financials

 BIOCON    GLENMARK PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
GLENMARK PHARMA
Mar-19
BIOCON /
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs707712 99.4%   
Low Rs554484 114.5%   
Sales per share (Unadj.) Rs91.9349.6 26.3%  
Earnings per share (Unadj.) Rs16.732.8 51.0%  
Cash flow per share (Unadj.) Rs24.244.3 54.5%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.3 47.4%  
Book value per share (Unadj.) Rs101.6198.6 51.2%  
Shares outstanding (eoy) m600.00282.17 212.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.91.7 401.4%   
Avg P/E ratio x37.718.2 207.0%  
P/CF ratio (eoy) x26.113.5 193.5%  
Price / Book Value ratio x6.23.0 206.2%  
Dividend payout %6.06.1 98.1%   
Avg Mkt Cap Rs m378,330168,625 224.4%   
No. of employees `0006.112.0 50.9%   
Total wages/salary Rs m11,65320,561 56.7%   
Avg. sales/employee Rs Th8,994.38,196.0 109.7%   
Avg. wages/employee Rs Th1,900.71,708.1 111.3%   
Avg. net profit/employee Rs Th1,635.3768.5 212.8%   
INCOME DATA
Net Sales Rs m55,14498,655 55.9%  
Other income Rs m1,4442,081 69.4%   
Total revenues Rs m56,588100,736 56.2%   
Gross profit Rs m15,88315,858 100.2%  
Depreciation Rs m4,4783,259 137.4%   
Interest Rs m7093,346 21.2%   
Profit before tax Rs m12,14011,335 107.1%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m2,1233,756 56.5%   
Profit after tax Rs m10,0269,250 108.4%  
Gross profit margin %28.816.1 179.2%  
Effective tax rate %17.533.1 52.8%   
Net profit margin %18.29.4 193.9%  
BALANCE SHEET DATA
Current assets Rs m48,22866,968 72.0%   
Current liabilities Rs m30,37640,211 75.5%   
Net working cap to sales %32.427.1 119.4%  
Current ratio x1.61.7 95.3%  
Inventory Days Days6883 82.0%  
Debtors Days Days8681 105.3%  
Net fixed assets Rs m64,13033,322 192.5%   
Share capital Rs m3,000282 1,063.1%   
"Free" reserves Rs m57,98055,770 104.0%   
Net worth Rs m60,98056,052 108.8%   
Long term debt Rs m15,76635,738 44.1%   
Total assets Rs m121,924132,888 91.7%  
Interest coverage x18.14.4 413.0%   
Debt to equity ratio x0.30.6 40.6%  
Sales to assets ratio x0.50.7 60.9%   
Return on assets %8.89.5 92.9%  
Return on equity %16.416.5 99.6%  
Return on capital %16.817.8 94.0%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50662,998 24.6%   
Fx outflow Rs m10,39922,859 45.5%   
Net fx Rs m5,10740,140 12.7%   
CASH FLOW
From Operations Rs m11,54613,242 87.2%  
From Investments Rs m-7,138-6,990 102.1%  
From Financial Activity Rs m-2,417-7,387 32.7%  
Net Cashflow Rs m2,103-2,971 -70.8%  

Share Holding

Indian Promoters % 40.4 48.3 83.6%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 6.9 121.7%  
FIIs % 10.7 34.4 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 56,727 193.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FULFORD INDIA  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 25, 2021 03:36 PM

TRACK BIOCON

BIOCON - ORCHID PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS